Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma

Molecular Therapy

Volumn 19, Issue 12, 2011, Pages 2201-2212

  Di Paolo, Daniela ^a   Ambrogio, Chiara ^b   Pastorino, Fabio ^a   Brignole, Chiara ^a   Martinengo, Cinzia ^b   Carosio, Roberta ^a   Loi, Monica ^a   Pagnan, Gabriella ^a   Emionite, Laura ^c   Cilli, Michele ^c   Ribatti, Domenico ^d   Allen, Theresa M ^e   Chiarle, Roberto ^b   Ponzoni, Mirco ^a   Perri, Patrizia ^a  

^a Laboratory of Oncology   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTIBODY; BORTEZOMIB; COATED CATIONIC LIPOSOME; DOXYCYCLINE; GANGLIOSIDE GD2 ANTIBODY; LIPID NANOPARTICLE; LIPOSOME; MATRIX METALLOPROTEINASE; NANOPARTICLE; SHORT HAIRPIN RNA; SILENCERSELECT; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL; CANCER INVASION; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG TARGETING; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SILENCING; GENETIC TRANSDUCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR CELL LINE; WILD TYPE;

MUS;

EID: 82955187719     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.142     Document Type: Article

References (50)

1. Maris, JM, Hogarty, MD, Bagatell, R and Cohn, SL (2007). Neuroblastoma. Lancet 369:2106-2120. (Pubitemid 46935947)
2. Cohn, SL, Pearson, AD, London, WB, Monclair, T, Ambros, PF, Brodeur, GM et al.; INRG Task Force. (2009). The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27:289-297.
3. Brodeur, GM (2003). Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3:203-216. (Pubitemid 37328872)
4. Longo, L, Borghini, S, Schena, F, Parodi, S, Albino, D, Bachetti, T et al. (2008). PHOX2A and PHOX2B genes are highly co-expressed in human neuroblastoma. Int J Oncol 33:985-991.
5. Mossé, YP, Laudenslager, M, Longo, L, Cole, KA, Wood, A, Attiyeh, EF et al. (2008). Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455:930-935.
6. nd, Zhang, J et al. (2008). Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455:975-978.
7. Janoueix-Lerosey, I, Lequin, D, Brugières, L, Ribeiro, A, de Pontual, L, Combaret, V et al. (2008). Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455:967-970.
8. Chen, Y, Takita, J, Choi, YL, Kato, M, Ohira, M, Sanada, M et al. (2008). Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455:971-974.
9. Palmer, RH, Vernersson, E, Grabbe, C and Hallberg, B (2009). Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 420:345-361.
10. Chiarle, R, Voena, C, Ambrogio, C, Piva, R and Inghirami, G (2008). The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8:11-23.
11. Webb, TR, Slavish, J, George, RE, Look, AT, Xue, L, Jiang, Q et al. (2009). Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 9:331-356.
12. Longo, L, Panza, E, Schena, F, Seri, M, Devoto, M, Romeo, G et al. (2007). Genetic predisposition to familial neuroblastoma: identification of two novel genomic regions at 2p and 12p. Hum Hered 63:205-211. (Pubitemid 46457589)
13. Passoni, L, Longo, L, Collini, P, Coluccia, AM, Bozzi, F, Podda, M et al. (2009). Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 69:7338-7346.
14. De Brouwer, S, De Preter, K, Kumps, C, Zabrocki, P, Porcu, M, Westerhout, EM et al. (2010). Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 16:4353-4362.
15. Carén, H, Abel, F, Kogner, P and Martinsson, T (2008). High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 416:153-159.
16. Bachetti, T, Di Paolo, D, Di Lascio, S, Mirisola, V, Brignole, C, Bellotti, M et al. (2010). PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma. PLoS ONE 5.
17. Mazot, P, Cazes, A, Boutterin, MC, Figueiredo, A, Raynal, V, Combaret, V et al. (2011). The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking. Oncogene 30:2017-2025.
18. McDermott, U, Iafrate, AJ, Gray, NS, Shioda, T, Classon, M, Maheswaran, S et al. (2008). Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 68:3389-3395.
19. Mossé, YP, Wood, A and Maris, JM (2009). Inhibition of ALK signaling for cancer therapy. Clin Cancer Res 15:5609-5614.
20. Choi, YL, Soda, M, Yamashita, Y, Ueno, T, Takashima, J, Nakajima, T et al.; ALK Lung Cancer Study Group. (2010). EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363:1734-1739.
21. Sasaki, T, Okuda, K, Zheng, W, Butrynski, J, Capelletti, M, Wang, L et al. (2010). The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 70:10038-10043.
22. Martinsson, T, Eriksson, T, Abrahamsson, J, Caren, H, Hansson, M, Kogner, P et al. (2011). Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res 71:98-105.
23. Gray, MJ, Van Buren, G, Dallas, NA, Xia, L, Wang, X, Yang, AD et al. (2008). Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst 100:109-120. (Pubitemid 351480563)
24. Whitehead, KA, Langer, R and Anderson, DG (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8:129-138.
25. Pagnan, G, Stuart, DD, Pastorino, F, Raffaghello, L, Montaldo, PG, Allen, TM et al. (2000). Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD (2)-targeted immunoliposomes: antitumor effects. J Natl Cancer Inst 92:253-261. (Pubitemid 30099785)
26. Pastorino, F, Stuart, D, Ponzoni, M and Allen, TM (2001). Targeted delivery of antisense oligonucleotides in cancer. J Control Release 74:69-75. (Pubitemid 32727610)
27. Pastorino, F, Brignole, C, Marimpietri, D, Pagnan, G, Morando, A, Ribatti, D et al. (2003). Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin Cancer Res 9:4595-4605. (Pubitemid 37248420)
28. Piva, R, Chiarle, R, Manazza, AD, Taulli, R, Simmons, W, Ambrogio, C et al. (2006). Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 107:689-697. (Pubitemid 43076395)
29. Ambrogio, C, Martinengo, C, Voena, C, Tondat, F, Riera, L, di Celle, PF et al. (2009). NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res 69:8611-8619.
30. Pastorino, F, Brignole, C, Marimpietri, D, Cilli, M, Gambini, C, Ribatti, D et al. (2003). Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 63:7400-7409. (Pubitemid 37413482)
31. Brignole, C, Pastorino, F, Marimpietri, D, Pagnan, G, Pistorio, A, Allen, TM et al. (2004). Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J Natl Cancer Inst 96:1171-1180. (Pubitemid 39207053)
32. Di Paolo, D, Brignole, C, Pastorino, F, Carosio, R, Zorzoli, A, Rossi, M et al. (2011). Neuroblastoma-targeted Nanoparticles Entrapping siRNA Specifically Knockdown ALK. Mol Ther 19:1131-1140.
33. Mujoo, K, Cheresh, DA, Yang, HM and Reisfeld, RA (1987). Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 47:1098-1104. (Pubitemid 17027936)
34. Brignole, C, Marimpietri, D, Pastorino, F, Nico, B, Di Paolo, D, Cioni, M et al. (2006). Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 98:1142-1157. (Pubitemid 44288789)
35. Pastorino, F, Brignole, C, Marimpietri, D, Sapra, P, Moase, EH, Allen, TM et al. (2003). Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 63:86-92. (Pubitemid 36070424)
36. Pastorino, F, Brignole, C, Di Paolo, D, Nico, B, Pezzolo, A, Marimpietri, D et al. (2006). Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculaturespecific ligands potentiates therapeutic efficacy. Cancer Res 66:10073-10082. (Pubitemid 44672061)
37. Nguyen, DN, Chen, SC, Lu, J, Goldberg, M, Kim, P, Sprague, A et al. (2009). Drug delivery-mediated control of RNA immunostimulation. Mol Ther 17:1555-1562.
38. Chambers, AF, Groom, AC and MacDonald, IC (2002). Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563-572. (Pubitemid 37328923)
39. Kwak, EL, Bang, YJ, Camidge, DR, Shaw, AT, Solomon, B, Maki, RG et al. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703.
40. Butrynski, JE, D'Adamo, DR, Hornick, JL, Dal Cin, P, Antonescu, CR, Jhanwar, SC et al. (2010). Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 363:1727-1733.
41. Merritt, WM, Bar-Eli, M and Sood, AK (2010). The dicey role of Dicer: implications for RNAi therapy. Cancer Res 70:2571-2574.
42. Tanaka, T, Mangala, LS, Vivas-Mejia, PE, Nieves-Alicea, R, Mann, AP, Mora, E et al. (2010). Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 70:3687-3696.
43. Yuan, F, Leunig, M, Huang, SK, Berk, DA, Papahadjopoulos, D and Jain, RK (1994). Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54:3352-3356. (Pubitemid 24225946)
44. Rössler, J, Taylor, M, Geoerger, B, Farace, F, Lagodny, J, Peschka-Süss, R et al. (2008). Angiogenesis as a target in neuroblastoma. Eur J Cancer 44:1645-1656.
45. Ribatti, D and Ponzoni, M (2005). Antiangiogenic strategies in neuroblastoma. Cancer Treat Rev 31:27-34. (Pubitemid 40246988)
46. Marzec, M, Liu, X, Wong, W, Yang, Y, Pasha, T, Kantekure, K et al. (2011). Oncogenic kinase NPM/ALK induces expression of HIF1a mRNA. Oncogene 30:1372-1378.
47. Pastorino, F, Loi, M, Sapra, P, Becherini, P, Cilli, M, Emionite, L et al. (2010). Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. Clin Cancer Res 16:4809-4821.
48. Raffaghello, L, Marimpietri, D, Pagnan, G, Pastorino, F, Cosimo, E, Brignole, C et al. (2003). Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Cancer Lett 197:205-209. (Pubitemid 36860012)
49. Yu, AL, Gilman, AL, Ozkaynak, MF, London, WB, Kreissman, SG, Chen, HX et al.; Children's Oncology Group. (2010). Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324-1334.
50. Pastorino, F, Di Paolo, D, Piccardi, F, Nico, B, Ribatti, D, Daga, A et al. (2008). Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res 14:7320-7329.